171 related articles for article (PubMed ID: 34751763)
1. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
Naci H; Smalley KR; Kesselheim AS
JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
[TBL] [Abstract][Full Text] [Related]
3. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
Wallach JD; Ramachandran R; Bruckner T; Ross JS
JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.
Egilman A; Wallach JD; Puthumana J; Zhang AD; Schwartz JL; Ross JS
J Gen Intern Med; 2021 Oct; 36(10):3281-3284. PubMed ID: 34131876
[No Abstract] [Full Text] [Related]
7. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
8. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
9. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
Milne CP; Cohen JP; Felix A; Chakravarthy R
Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
[TBL] [Abstract][Full Text] [Related]
10. [Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice].
Carcas AJ; Abad Santos F; Sánchez Perruca L; Dal-Ré R
Med Clin (Barc); 2015 Nov; 145(10):452-7. PubMed ID: 25913907
[No Abstract] [Full Text] [Related]
11. Conducting prospective sequential surveillance in real-world dynamic distributed databases.
Maro JC; Eworuke E; Hou L; Welch EC; Goulding MR; Izem R; Lee JY; Toh S; Fireman B; Nguyen MD
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1331-1335. PubMed ID: 32449261
[No Abstract] [Full Text] [Related]
12. Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary.
Girman CJ; Ritchey ME; Zhou W; Dreyer NA
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):439-442. PubMed ID: 30515910
[No Abstract] [Full Text] [Related]
13. FDA's first active medical product surveillance eyes antidiabetic-MI link.
Thompson CA
Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
[No Abstract] [Full Text] [Related]
14. A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative.
Brown JD
J Manag Care Spec Pharm; 2020 Aug; 26(8):1050. PubMed ID: 32715968
[TBL] [Abstract][Full Text] [Related]
15. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
16. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
Vastag B
Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
[No Abstract] [Full Text] [Related]
17. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
Omae K; Onishi A; Sahker E; Furukawa TA
JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
Mofid S; Bolislis WR; Kühler TC
Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
[TBL] [Abstract][Full Text] [Related]
19. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
20. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
